Collagen Part 1: Why Collagen Is the Endpoint the Field Is Chasing
Beyond the Surface is an educational series from MedX Health exploring the science behind objective skin measurement. Throughout this series, we'll examine the technologies, methodologies, and research principles shaping the future of skin health, from biological measurement and longitudinal analysis to data integrity, clinical endpoints, and evidence generation.Our goal isn't to promote a product. It's to contribute to the broader conversation about how objective measurement can help researchers generate stronger evidence, improve study design, and better understand skin biology over time.
Ask a room of skin researchers what they would most like to measure non-invasively, and collagen comes up fast. It is the structural protein that gives skin its firmness and resilience, and its decline is central to how skin ages. Collagen falls with age and with sun exposure, and preserving or rebuilding it is the stated goal of a large share of dermatology and cosmetic research. If you could track collagen directly, over time, without cutting into the skin, you would have a window into the process almost every intervention in this space is trying to influence.
That is why sponsors ask for it by name. In anti-aging and cosmetic research especially, a collagen endpoint is often the center of the claim a brand wants to make, and the strength of that claim depends on the strength of the collagen evidence behind it. A CRO that can offer a credible, non-invasive collagen measurement is offering the exact endpoint sponsors are trying to build their programs around. That is a commercial advantage, not only a scientific one.
The problem has always been access. The reference method for collagen is a biopsy, which means removing tissue. A biopsy is invasive, it captures a single point in time, and you cannot repeat it visit after visit on the same spot in a living subject. That constraint has shaped skin research for decades. It is also why a non-invasive collagen readout has been such a sought-after and elusive goal.
What makes collagen worth this series is not a claim that the problem is solved. It is that independent evidence shows a non-invasive collagen readout can track real collagen biology.
Two lines of independent work are worth knowing. In one study, researchers used a SIAscopy-based collagen assessment to stratify aged, sun-exposed skin, with a biochemical measure from biopsy serving as the reference. Subjects with low collagen responded roughly six times more often to anti-aging cosmeceuticals, and collagen status was the strongest single predictor of who responded. In separate independent work, the collagen readout declined with increasing age and sun exposure, the exact direction that established collagen biology predicts. That second finding is what scientists call construct validity: the measure moves the way the underlying biology says it should.
Taken together, these independent findings show the readout behaves like dermal collagen and that outside investigators have treated it as informative. What they do not yet include is a direct calibration to an absolute collagen level against tissue. That is a single, well-defined study, not a flaw in the method, and it is the clear next step from strong ground rather than a question mark hanging over the work. The honest position and the confident one are the same here: a non-invasive readout that tracks collagen, with a defined path to full validation.
This is the honest position, and we think it is the compelling one. Collagen is the endpoint the field is chasing. Few non-invasive tools measure it at all. A readout that behaves like collagen, that can be captured at every visit without a biopsy, is a genuinely different capability.
How that measurement actually works, and exactly what it can and cannot claim, is the subject of Part 2. Read our first